Myovant Sciences Ltd. (NYSE: MYOV) expected to report earnings of -$0.10 per share

Analysts predict that Myovant Sciences Ltd. (NYSE:MYOV – Get Rating) will post ($0.10) earnings per share (EPS) for the current fiscal quarter, reports Zacks Investment Research. Two analysts provided earnings estimates for Myovant Sciences. The lowest EPS estimate is ($0.12) and the highest is ($0.08). Myovant Sciences reported earnings per share of ($0.67) in the same quarter last year, suggesting a positive year-over-year growth rate of 85.1%. The company is expected to release its next quarterly results on Monday, January 1.

According to Zacks, analysts expect Myovant Sciences to report annual earnings of ($1.45) per share for the current fiscal year, with EPS estimates ranging from ($1.45) to ($1.45) per share. $44). For the next fiscal year, analysts expect the company to post earnings of ($1.55) per share. Zacks Investment Research’s EPS calculations are an average average based on a survey of research companies that track Myovant Sciences.

MYOV has been the subject of several analyst reports. Robert W. Baird reduced his price target on Myovant Sciences from $30.00 to $20.00 in a Wednesday, April 13 research note. SVB Leerink reduced its price target on Myovant Sciences from $19.00 to $12.00 and set a “market performance” rating on the stock in a Wednesday, April 13 report. StockNews.com began covering Myovant Sciences in a report on Thursday, March 31. They issued a “hold” rating on the stock. Finally, Zacks Investment Research upgraded Myovant Sciences from a “sell” rating to a “hold” rating in a Saturday, May 14 report. Four investment analysts gave the stock a hold rating and one gave the stock a buy rating. According to data from MarketBeat, Myovant Sciences has an average rating of “Hold” and a consensus target price of $18.50.

In other Myovant Sciences news, Ferreira insider Juan Camilo Arjona sold 1,922 shares of the company in a trade on Tuesday, April 5. The stock was sold at an average price of $13.78, for a total transaction of $26,485.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available on the SEC’s website. Additionally, General Counsel Matthew Lang sold 2,436 shares of the company in a transaction on Tuesday, April 5. The stock was sold at an average price of $13.78, for a total value of $33,568.08. The disclosure of this sale can be found here. In the past 90 days, insiders have sold 16,992 shares of the company worth $192,079. Insiders of the company hold 5.10% of the shares of the company.

Several hedge funds and other institutional investors have recently changed their holdings to MYOV. Bank of America Corp DE increased its stake in shares of Myovant Sciences by 43.1% in the second quarter. Bank of America Corp DE now owns 9,671 shares of the company valued at $220,000 after buying 2,911 additional shares last quarter. Morgan Stanley increased its stake in Myovant Sciences by 9.2% during the second quarter. Morgan Stanley now owns 240,056 shares of the company worth $5,465,000 after buying 20,212 more shares last quarter. BlackRock Inc. increased its stake in Myovant Sciences by 7.3% during the third quarter. BlackRock Inc. now owns 1,135,635 shares of the company worth $25,484,000 after purchasing an additional 77,322 shares in the last quarter. Barclays PLC increased its stake in Myovant Sciences by 280.4% during the third quarter. Barclays PLC now owns 5,147 shares in the company worth $116,000 after buying an additional 3,794 shares last quarter. Finally, Geode Capital Management LLC increased its stake in Myovant Sciences by 4.9% in the 3rd quarter. Geode Capital Management LLC now owns 361,806 shares of the company worth $8,118,000 after purchasing an additional 16,983 shares last quarter. 32.55% of the shares are held by institutional investors and hedge funds.

Shares of NYSE MYOV traded down $0.97 during Thursday’s midday session, hitting $11.83. 732,426 shares of the company were traded, against an average volume of 803,351. The stock has a market capitalization of $1.13 billion, a price-earnings ratio of -5.35 and a beta of 2.78 . Myovant Sciences has a 1-year minimum of $7.67 and a 1-year maximum of $27.43. The company has a 50-day moving average of $10.77 and a 200-day moving average of $13.13.

Company profile Myovant Sciences (Get a rating)

Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, is focused on the development and commercialization of therapies for women’s health and endocrine diseases. The Company’s lead product is relugolix, a once-daily oral small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding associated with uterine fibroids, pain associated with endometriosis and advanced prostate cancer.

Recommended Stories

Get a Free Copy of Zacks’ Research Report on Myovant Sciences (MYOV)

For more information on Zacks Investment Research’s research offerings, visit Zacks.com

Earnings History and Estimates for Myovant Sciences (NYSE:MYOV)

This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Should you invest $1,000 in Myovant Sciences right now?

Before you consider Myovant Sciences, you’ll want to hear this.

MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Myovant Sciences didn’t make the list.

While Myovant Sciences currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the 5 actions here